GSK poaches new drug development chief Chris Corsico from Boehringer, dividing R&D into two groups

GlaxoSmithKline is continuing its makeover in the executive team that runs its R&D group.

The pharma giant tells me that Chris Corsico, who had been chief medical officer at the private German outfit Boehringer Ingelheim, is stepping over to GSK as the head of drug development.